The risks of statin use in pregnancy: A systematic review

Journal of Clinical Lipidology

Volumn 10, Issue 5, 2016, Pages 1081-1090

  Karalis, Dean G ^a   Hill, Alethea N ^b   Clifton, Shari ^c   Wild, Robert A ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Congenital anomalies; Pregnancy; Pregnancy complications; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; CASE REPORT; CASE STUDY; COHORT ANALYSIS; CONGENITAL MALFORMATION; DISEASE REGISTRY; EMBASE; HUMAN; MEDLINE; NONHUMAN; OBSERVATIONAL STUDY; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; CLINICAL TRIAL (TOPIC); FEMALE; GENETICS; HYPERLIPIDEMIAS; PRE-ECLAMPSIA; RISK;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; RISK;

EID: 84994311158     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2016.07.002     Document Type: Review

References (25)

1. 1 U.S Food and Drug Administration. Available at: http://www.fda.gov. Accessed May 3, 2016.
2. 2 Dostal, L.A., Schardein, J.L., Anderson, J.A., Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits. Teratology 50 (1994), 387–394.
3. 3 Minsker, D.H., MacDonald, J.S., Robertson, R.T., Bokelman, D.L., Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Teratology 28 (1983), 449–456.
4. 4 Jacobson, T.A., Maki, K.C., Orringer, C., et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol 9 (2015), S1–S122.
5. 5 Women with FH and pregnancy. Available at: https://thefhfoundation.org. Accessed May 3, 2016.
6. 6 Gagne, J.J., Maio, V., Berghella, V., Louis, D.Z., Gonella, J.S., Prescription drug use during pregnancy: a population based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 64 (2008), 1125–1132.
7. 7 Costantine, M.M., Cleary, K., Hebert, M.F., et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol 214 (2016), 720.e1–720.e17.
8. 8 Manson, J.M., Freyssinges, C., Ducrocq, M.B., Stephenson, W.P., Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 10 (1996), 439–446.
9. 9 Edison, R.J., Muenke, M., Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 350 (2004), 1579–1582.
10. 10 Edison, R.J., Muenke, M., Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet 131A (2004), 287–298.
11. 11 Pollack, P.S., Shields, K.E., Burnett, D.M., et al. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol 73 (2005), 888–896.
12. 12 Peterson, E.E., Mitchell, A.A., Carey, J.C., et al. Maternal exposure to statins and risk for birth defects: A case-series approach. Am J Med Genet 146A (2008), 2701–2705.
13. 13 Taguchi, N., Rubin, E.T., Hosokawa, A., et al. Prenatal exposure to HMG-CoA reductase inhibitors: Effects on fetal and neonatal outcome. Reprod Toxicol 26 (2008), 175–177.
14. 14 Winterfield, U., Allignol, A., Panchaud, A., et al. Pregnancy outcome following maternal exposure to statins: a multicenter prospective study. BJOG 120 (2013), 463–471.
15. 15 Bateman, B.T., Hernandez-Diaz, S., Fischer, M.A., et al. Statins and congenital malformations: cohort study. Br Med J, 350, 2015, h1035.
16. 16 Ofori, B., Ray, E., Berard, A., Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 64 (2007), 496–509.
17. 17 Colvin, L., Slack-Smith, L., Stanley, F.J., Bower, C., Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. Pharmacoepidemiol Drug Saf 19 (2010), 1137–1150.
18. 18 Toleikyte, I., Retterstol, K., Leren, T.P., Iversen, P.O., Pregnancy outcomes in familial hypercholesterolemia a registry-based study. Circulation 124 (2011), 1606–1614.
19. 19 Kazmin, A., Garcia-Bournissen, F., Koren, G., Risk of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 29 (2007), 906–908.
20. 20 Kusters, D.M., Lahsinoui, H.H., van de Post, J.A.M., et al. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther 10 (2012), 363–378.
21. 21 Godrey, L.M., Erramouspe, J., Cleveland, K.W., Teratogenic risk of statins in pregnancy. Ann Pharmacother 46 (2012), 1419–1424.
22. 22 Zarek, J., Delano, K.E., Nickel, C., Laskin, C.A., Koren, G., Are statins teratogenic in humans? Addressing the safety of statins in light of potential benefits during pregnancy. Expert Rev Obstet Gynecol 8 (2013), 513–524.
23. 23 Macintosh, M.C., Fleming, K.M., Bailey, J.A., et al. Perinatal mortality and congenital anomalies in babies of women with Type 1 or Type 2 diabetes in England, Wales, and Northern Ireland: population based study. Br Med J 333 (2006), 177–180.
24. 24 Satpathy, H.K., Fleming, A., Frey, D., et al. Maternal obesity and pregnancy. Postgrad Med 120 (2008), 1–9.
25. 25 Khoury, M.J., James, L.M., Erickson, J.D., On the use of affected controls to address recall bias in case-control studies of birth defects. Teratology 49 (1994), 273–281.